EL7.AI
StocksMedium•30 March 2026•
1 min read

Aprea Therapeutics Reports Positive Phase 1 Trial Data for Cancer Drug APR-1051

Key Facts

1Aprea Therapeutics (APRE) confirmed a partial response (PR) in its Phase 1 ACESOT-1051 trial for the drug APR-1051.
2The drug APR-1051 targets WEE1 inhibition in biomarker-defined cancers, showing a favorable safety profile without class-limiting toxicity to date.
3The company expects to provide a further update on the clinical trial results in the second quarter of 2026.

Aprea Therapeutics (Nasdaq: APRE) announced positive early clinical data from its Phase 1 ACESOT-1051 trial evaluating the drug APR-1051. The study confirmed a partial response (PR) in patients with biomarker-defined cancers, suggesting potential efficacy for the WEE1 inhibitor. Notably, the drug demonstrated a favorable safety profile with no class-limiting toxicities reported to date. This clinical proof of concept is a significant milestone as the company seeks to establish the treatment as a best-in-class option with an improved therapeutic index. Aprea expects to provide a further update on the clinical trial results in the second quarter of 2026. Such positive early-stage data is typically viewed as a strong catalyst for clinical-stage biotech companies, bolstering investor confidence in the pipeline.